Together, our findings suggests that RAPA + Honokiol combination treatment can be a novel therapeutic option for renal cancer, with particular importance to post-transplantation cancer; and Honokiol can overcome the limitation of prolonged RAPA treatment, and restrict RAPA-induced Akt activation. This evidence concerns the gene AKT1 and cancer.